Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors

Sensitivity and meta-regression analysis of randomized trials

Sara Pilotto, Massimo Di Maio, Umberto Peretti, Stefania Kinspergher, Matteo Brunelli, Francesco Massari, Isabella Sperduti, Diana Giannarelli, Filippo De Marinis, Giampaolo Tortora, Emilio Bria

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: We performed a sensitivity and meta-regression analysis, cumulating all randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus chemotherapy in advanced EGFR mutant NSCLC, to investigate the potential role of additional clinico-pathological predictors of TKIs efficacy. Results: With regard to progression-free survival (PFS), a significant interaction according to ethnicity (Asian versus Caucasian versus mixed) and to trial design (retrospective versus prospective EGFR analysis), was found; a trend toward significance with regard to type of drug (gefitinib versus erlotinib versus afatinib) was determined. No statistically significant differences in survival were observed. With regard to response, a significant interaction according to ethnicity, trial design and type of drug, was found. Conclusion: These data, together with a deeper characterization of the molecular background sustaining the oncogenic process, may contribute to create a clinico-pathologic predictive model, aimed to improve the magnitude of benefit expected from the use of targeted agents.

Original languageEnglish
Pages (from-to)135-145
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume90
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Meta-Analysis
Regression Analysis
Mutation
Drug Design
Disease-Free Survival
Drug Therapy
Survival
Pharmaceutical Preparations
gefitinib
BIBW 2992
Adenocarcinoma of lung
Erlotinib Hydrochloride

Keywords

  • Afatinib
  • Erlotinib
  • Ethnicity
  • Gefitinib
  • Lung cancer
  • Meta-analysis
  • Trial design

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors : Sensitivity and meta-regression analysis of randomized trials. / Pilotto, Sara; Di Maio, Massimo; Peretti, Umberto; Kinspergher, Stefania; Brunelli, Matteo; Massari, Francesco; Sperduti, Isabella; Giannarelli, Diana; De Marinis, Filippo; Tortora, Giampaolo; Bria, Emilio.

In: Critical Reviews in Oncology/Hematology, Vol. 90, No. 2, 2014, p. 135-145.

Research output: Contribution to journalArticle

Pilotto, Sara ; Di Maio, Massimo ; Peretti, Umberto ; Kinspergher, Stefania ; Brunelli, Matteo ; Massari, Francesco ; Sperduti, Isabella ; Giannarelli, Diana ; De Marinis, Filippo ; Tortora, Giampaolo ; Bria, Emilio. / Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors : Sensitivity and meta-regression analysis of randomized trials. In: Critical Reviews in Oncology/Hematology. 2014 ; Vol. 90, No. 2. pp. 135-145.
@article{4ffd21a908e1440ab8ee1312619ec496,
title = "Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials",
abstract = "Purpose: We performed a sensitivity and meta-regression analysis, cumulating all randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus chemotherapy in advanced EGFR mutant NSCLC, to investigate the potential role of additional clinico-pathological predictors of TKIs efficacy. Results: With regard to progression-free survival (PFS), a significant interaction according to ethnicity (Asian versus Caucasian versus mixed) and to trial design (retrospective versus prospective EGFR analysis), was found; a trend toward significance with regard to type of drug (gefitinib versus erlotinib versus afatinib) was determined. No statistically significant differences in survival were observed. With regard to response, a significant interaction according to ethnicity, trial design and type of drug, was found. Conclusion: These data, together with a deeper characterization of the molecular background sustaining the oncogenic process, may contribute to create a clinico-pathologic predictive model, aimed to improve the magnitude of benefit expected from the use of targeted agents.",
keywords = "Afatinib, Erlotinib, Ethnicity, Gefitinib, Lung cancer, Meta-analysis, Trial design",
author = "Sara Pilotto and {Di Maio}, Massimo and Umberto Peretti and Stefania Kinspergher and Matteo Brunelli and Francesco Massari and Isabella Sperduti and Diana Giannarelli and {De Marinis}, Filippo and Giampaolo Tortora and Emilio Bria",
year = "2014",
doi = "10.1016/j.critrevonc.2013.11.005",
language = "English",
volume = "90",
pages = "135--145",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors

T2 - Sensitivity and meta-regression analysis of randomized trials

AU - Pilotto, Sara

AU - Di Maio, Massimo

AU - Peretti, Umberto

AU - Kinspergher, Stefania

AU - Brunelli, Matteo

AU - Massari, Francesco

AU - Sperduti, Isabella

AU - Giannarelli, Diana

AU - De Marinis, Filippo

AU - Tortora, Giampaolo

AU - Bria, Emilio

PY - 2014

Y1 - 2014

N2 - Purpose: We performed a sensitivity and meta-regression analysis, cumulating all randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus chemotherapy in advanced EGFR mutant NSCLC, to investigate the potential role of additional clinico-pathological predictors of TKIs efficacy. Results: With regard to progression-free survival (PFS), a significant interaction according to ethnicity (Asian versus Caucasian versus mixed) and to trial design (retrospective versus prospective EGFR analysis), was found; a trend toward significance with regard to type of drug (gefitinib versus erlotinib versus afatinib) was determined. No statistically significant differences in survival were observed. With regard to response, a significant interaction according to ethnicity, trial design and type of drug, was found. Conclusion: These data, together with a deeper characterization of the molecular background sustaining the oncogenic process, may contribute to create a clinico-pathologic predictive model, aimed to improve the magnitude of benefit expected from the use of targeted agents.

AB - Purpose: We performed a sensitivity and meta-regression analysis, cumulating all randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus chemotherapy in advanced EGFR mutant NSCLC, to investigate the potential role of additional clinico-pathological predictors of TKIs efficacy. Results: With regard to progression-free survival (PFS), a significant interaction according to ethnicity (Asian versus Caucasian versus mixed) and to trial design (retrospective versus prospective EGFR analysis), was found; a trend toward significance with regard to type of drug (gefitinib versus erlotinib versus afatinib) was determined. No statistically significant differences in survival were observed. With regard to response, a significant interaction according to ethnicity, trial design and type of drug, was found. Conclusion: These data, together with a deeper characterization of the molecular background sustaining the oncogenic process, may contribute to create a clinico-pathologic predictive model, aimed to improve the magnitude of benefit expected from the use of targeted agents.

KW - Afatinib

KW - Erlotinib

KW - Ethnicity

KW - Gefitinib

KW - Lung cancer

KW - Meta-analysis

KW - Trial design

UR - http://www.scopus.com/inward/record.url?scp=84897571862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897571862&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.11.005

DO - 10.1016/j.critrevonc.2013.11.005

M3 - Article

VL - 90

SP - 135

EP - 145

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -